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1. Abstract
The difficulty to find compatible donors for bone marrow transplantation makes the need for 
an alternative source of HSCs urgent. HSC derived from patient-specific iPS cells are ideal 
candidates for this purpose. Nevertheless, although HSCs are the best characterized adult 
stem cells, the in vitro generation and expansion of bone fide HSCs still has not been achieved 
without transgene insertion. Successful derivation of HSCs from ES cells or iPS cells will require 
a comprehensive understanding of inductive signals and downstream effectors involved in the 
normal arising of HSCs during embryonic development. BMP and Wnt signaling pathways play 
a very important role in this differentiation process. Here, we report how BMP and Wnt signaling 
inhibition cooperatively alter the differentiation of Flk1+PDGFRα- cells after reculture in serum-
free, feeder layer-free conditions. This data will be useful in determining the factors that have 
to be added to a chemically defined culture medium aimed at derivation of bone fide HSC in 
vitro. In the second part of this master’s project, we studied the spatial and temporal localization 
requirements of Etv2 expression, a key regulator of the earliest events in the development of 
the hematopoietic and vascular systems. To gain more insight on this matter, we conditionally 
knocked-in Etv2 in the early endothelial compartment, using a Tie2Cre system. This leaded 
to an embryonically lethal phenotype by E11.5, and most interestingly, to the expansion of a 
VE-Cadherin+CD45+ population in the E10.5 yolk sac. We believe that these cells represent a 
increased pool of immature pre-definitive hematopoietic stem cells, thus underlining further 
the importance of Etv2 in the differentiation process towards hematopoietic, and endothelial 
lineages in the mouse embryo.
Key words: Mater title - Specialization - Hematopoietic stem cell - Etv2/ER71 - Embryonic stem 
cell
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2. Introduction
Embryonic Stem (ES) cells are derived from the inner cell mass of preimplantation or peri-
implantation blastocysts. They were first isolated from mouse blastocysts in 1981.1,2 ES cells 
have the ability to self-renew in vitro, to differentiate into tissues derived from all 3 embryonic 
germ layers (pluripotency) and to form teratomas when injected in immunodeficient mice. They 
also have the capacity to contribute to all tissues of chimeric mice, including the germ-line, upon 
microinjection into a host blastocyst.3 ES cells can be maintained in an undifferentiated state 
by numerous cell intrinsic and environmental factors and can thus be cultured and expanded in 
vitro.4,5 Differentiation into various tissue types can also be induced in vitro, including towards 
hematopoietic cells.6,7 Direct reprogramming of mouse fibroblasts to induced pluripotent 
stem (iPS) cells by overexpression of four transcription factors (Oct4, Sox2, Klf4 and c-Myc) 
was achieved in 2006.8 The following year, it was shown to be achievable with human cells as 
well,9,10,11 permitting to derive patient-specific ES cell equivalents and opening new frontiers 
for regenerative medicine, disease modelling and drug discovery. Nowadays, iPS cells can be 
generated from various mouse, human, and other animals somatic cell types, using viral, non-
viral or chemical methodologies.12,13 iPS cells are now widely accepted as closely resembling 
ES cells in their morphological, molecular and developmental attributes, although they may not 
have identical  global gene expression patterns14 and epigenetic state.15,16,17,18,19
Repopulation of the entire hematopoietic system for extensive period of time can be achieved by 
the transplantation of a single hematopoietic stem cell (HSC) in  a suitable adult host.20 Those 
cells have thus an incredible potential  to cure hematological disorders, and have been used 
to treat such diseases for over 40 years.21,22 However, the difficulty to find compatible donors 
to carry out transplantation makes the need for an alternative source of HSCs urgent. HSC 
derived from patient-specific iPS cells are amongst the best candidates for these replacement cell 
therapies. However, although HSCs are the best characterized adult stem cells, and despite the 
fact that it is relatively easy to generate multipotent hematopoietic progenitors with extensive 
proliferative capacity from ES cells and iPS cells,6,7,23 the generation and expansion of HSCs 
from ES-like cells that haven’t been genetically modified remains a challenge;24,25 most studies 
reported weak and inconsistent repopulation capacity after irradiation in transplantation assays. 
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Therefore, successful derivation of HSCs from ES cells or iPS cells will require a comprehensive 
understanding of inductive signals and downstream effectors involved in the normal arising of 
HSCs during embryonic development.
The developmental process of the hematopoietic system and signaling pathways that regulates 
it are generally conserved throughout vertebrate evolution, including humans. Embryonic 
hematopoiesis is generally divided in two  parts: primitive and definitive. Primitive hematopoiesis 
is restricted to the yolk sac and starts around embryonic day (E) 7 in mouse. It gives rise to 
primitive erythrocytes, macrophages and megakaryocytes.26,27 Definitive hematopoiesis occurs 
at different places and different times in the mouse conceptus: yolk sac, placenta, vitelline and 
umbilical arteries, and para-aortic splanchnopleura (P-Sp), which later contains the aorta, 
gonads and mesonephros (AGM). It starts at around E8, and gives rise to all blood lineages and 
ultimately to definitive HSCs at around E10.5.26,27 The relative contribution of each of the above 
sites to the final pool of adult HSCs is still largely unknown. Within the AGM, HSCs emerge 
from an hemogenic endothelium located in the ventral wall of the dorsal aorta. 28,29,30,31,32 
The idea that hematopoietic cells and endothelial cells emerge from a common precursor 
was formulated for the first time more than 90 years ago by Florence Sabin, who observed 
the formation of blood islands from undifferentiated mesoderm in the yolk sac of the chick 
embryo.33,34 She noted that these mesodermal cells differentiated into solid angioblastic cords 
of cells that had the potential to mature into endothelial cells, blood plasma, and primitive 
erythroids.35 These observations were the seed to the idea that a common multipotential 
precursor, the hemangioblast, might exist for endothelial and hematopoietic lineages.31,32,36 The 
existence of cells that have such potential has been proven in vitro,23,37 and in vivo.38 However, 
after decades of debate on the matter, a clear unifying definition of this precursor cell has is 
still missing. Our lab defends a hemogenic endothelium model that is a little different from the 
classical view on this developmental process. We believe that all hematopoietic precursor cells 
originate from extraembronic mesoderm cells, that migrate to the embryo proper, at around 
E7.5-E8.
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In the mouse embryo, at the onset of gastrulation (around E6.5), the primitive streak is formed 
by epiblast cells from the posterior part of the embryo that undergo an epithelial to mesenchymal 
transition. The mesoderm emerges from the primitive streak and migrates away from it laterally 
and anteriorly. It will give rise to blood, endothelium, connective tissue, and skeletal, smooth 
and cardiac muscle. All nascent mesodermal cells express Brachyury (Bry).39,40,41 Cells from 
the anterior regions of the primitive streak preferentially express Foxa2 and Goosecoid, when 
the ones from the posterior regions express HoxB1 and Evx1.6 Epiblast cells that  will give rise 
to the extraembryonic mesoderm, which forms the hematopoietic, endothelial and vascular 
smooth muscle cells of the yolk sac, allantois and amnion, are the first mobilized and traverse the 
posterior primitive streak. Generation of cranial, cardiac, paraxial and axial mesoderm occurs as 
gastrulation proceeds and cells migrate through more anterior parts of the primitive streak. Bone 
morphogenic protein 4 (BMP4), Nodal and members of the Wnt family are essential for those 
developmental steps.6 
The subset of Bry-expressing (Bry+) mesodermal cells that express Fetal liver kinase 1 (Flk1, 
Kdr, or Vascular endothelial growth factor receptor 2, VEGFR2) but not Platelet-derived growth 
factor receptor α (PDGFRα) will become proximal and extraembryonic mesoderm, the cells that 
express PDGFRα but not Flk1 will become paraxial mesoderm and the ones that express both 
Etv2+/- Etv2-/-
PDGFR
Flk1
PDGFR
Flk1
Figure 1. Flk1 and PDGFRα expression patterns in E7.5 mouse embryos
Immunostaining and fluorescence imaging of Etv2+/- and Etv2-/- E7.5 embryos. No Flk1+ 
extraembryonic mesoderm formation in the full knockout embryo. PDGFRα expression 
is unaffected. 40x, scale bar = 100µm. Courtesy of Dr. Hiroshi Kataoka
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represents a transient, undifferentiated multipotential population.42,43,44 These double-positive 
cells eventually lose the expression of either Flk1 or PDGFRα and become single-positive cells. 
Flk1+PDGFRα- cells represents the population that we affirm have the potential to migrate 
towards the dorsal aorta at around E7.5-E8.0, and become angioblasts. Combined BMP, Notch 
and Wnt signaling is required for Flk1+ mesoderm formation.45,46
Flk1 is a receptor tyrosine kinase that binds Vascular endothelial growth factor (VEGF) with high 
affinity. It is a marker for extraembryonic mesoderm (which includes lateral plate mesoderm, 
yolk sac mesoderm), allantois, and cardiac crest.47 (Fig. 1) Flk1 is necessary cell-autonomously 
for both endothelial and hematopoietic development, in vitro and in vivo.48,49 Flk1-/- and VEGF+/- 
knockout mice display similar phenotypes: defects in the yolk sac blood islands, blood vessels, 
and endocardium. They die around E9.5, indicating that VEGF is one of the most important 
ligand of Flk1 during developmental hematopoiesis and angiogenesis and that this signaling is 
necessary for the establishment of both hematopoietic and vascular systems.46 Despite its crucial 
role in the onset of hematopoiesis an generation of the circulatory system, the mechanisms of 
Flk1+ mesoderm formation and differentiation are still poorly understood. Extraembryonic 
mesoderm Flk1+ cells can give rise to both hematopoietic and endothelial lineages are can thus 
be considered as somehow equivalent to the conceptual hemangioblast. These cells may then 
activate a GATA2/Fli1/Scl recursively wired gene-regulatory circuit,50 (Fig. 2) and differentiate
both in vitro and in vivo into either definitive endothelial cells, or hemogenic endothelial 
cells.23,37,38,51 Both endothelial cell types are marked by coexpression of the transcription factor 
Scl (also known as Tal1)52, Tie2,53,54  and Vascular endothelial cadherin (VE-Cad, also known as 
Figure 2. A fully connected triad of 
hematopoietic transcription factors
The GATA2/Fli1/Scl triad with putative initiators. 
Direct interactions are represented by solid lines, 
dashed lines represent indirect interactions. 
Copied from reference 50.
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Figure 3. Model of blood cell formation from lateral plate mesoderm and yolk sac mesoderm
The specific phenotype of the cell populations, as well as the key regulators, transcription factors, or signaling 
pathways, involved in hematopoietic development are indicated.
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Cdh5) expression.51,55,56,57 These two cell types are distinguished by the fact that the hemogenic 
endothelial cells transiently expressed Runt-related transcription factor 1(Runx1, also called 
AML1) during their differentiation from Flk1+ mesoderm.58(unpublished data) 
Flk1+ extraembryonic mesoderm cells can also differentiate into proerythroblasts, which are early 
primitive erythroid progenitors that express GATA1 and are CD41+Ter119+c-Kitlow/-.26,52,59,60 
This process depends on Runx1 expression,58,61,62 and is supposed to require Wnt signaling.59
Hemogenic endothelial cells were named this way because of their potential to differentiate 
into hematopoietic cells, or definitive endothelial cells. 26,38,63,64 CD41 is the earliest marker 
for  hematopoietic differentiation.65 Differentiation towards pre-definitive-HSC cells, which 
are Runx1+VE-Cadlowc-Kit+CD45+, depends on Notch signaling.26,52,38,59,66,67.(Fig. 3) The key 
transcription factor implicated in this process is Runx1, which is required for the transition 
from endothelial to hematopoietic cell.68 Virtually all adult hematopoietic cells are derived 
from Runx1-expressing cells.26,69 Runx1-/- mice die around E12.5 from a lack of definitive 
hematopoiesis, although they display almost normal primitive hematopoiesis.62,70 There is rising 
evidence that Runx1 also has a major role in priming Flk1+ extraembryonic mesoderm cells: 
Runx1+Gata1- cells would become hemogenic endothelial cells, Runx1-Gata1- cells appear to be 
fated towards definitive endothelial lineage, and Runx1+Gata1+ cells seem to be directed towards 
Flk1 Runx1 Gata1
Figure 4. Expression pattern of Flk1, Runx1, and Gata1 in the E7.5 mouse embryo
Immunohistochemistry staining shows that Flk1 is broadly expressed in the whole extraembryonic 
mesoderm. β-Gal staining of a Runx1LacZ/Wt shows that Runx1 expression is limited to the proximal 
yolk sac at that stage. Gata1 expression is restricted to the blood isalnds at E7.5, as shown by 
immunohistochemistry. Courtesy of Professor Shin-Ichi Nishikawa
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primitive erythropoiesis.58,61,62 (unpublished data) Thus, the localization of the cells within the 
Flk1+ extraembryonic mesoderm plays a major role in the differentiation pattern towards one 
of these three fates: at E7.5, Gata1 expression is limited to the blood island region, and Runx1 
expression to the proximal yolk sac. (Fig. 4)
BMPs are members of the Transforming growth factor- β (TGF- β) superfamily of ligands. They 
induce type I and type II serine-threonine kinase receptors association. ALK2, -3, and -6 are the 
Type I receptors responsive to BMPs. Type II receptors then phosphorylate and activate type I 
serine-threonine kinase receptors, which in turn phosphorylate two Receptor-activated Smad 
proteins (R-Smads: Smad1, -2, -3, -5 or -8), which bind the Common-Smad (Co-Smad), Smad4. 
Smad1, -5, and -8 are implicated in BMP signaling, when Smad2, and -3 are implicated in TGF-β 
signaling. The trimeric Smad complexes then translocates to the nucleus, where they interact 
with other transcriptional regulators to control expression of target genes.71,72,73,74,75 (Fig. 5) 
BMP4 is essential during mouse embryonic development for gastrulation and mesoderm 
formation, as BMP4 -deficient mice are embryonic lethal due to severe mesodermal defects.76 It 
has been shown that BMP4 induces the formation of Flk1+ and hematopoietic cells in in vitro cell 
cultures,43,77 and to activate hematopoietic transcription factors such as Runx1 and Gata2.78,79,80 
(Fig. 3) It has been suggested that BMP signaling plays a two-step role during ESC differentiation 
towards the hematopoietic lineage: it mediates dorsoventral patterning and induces ventral-
posterior mesoderm at first, and then promotes blood specification from preformed mesodermal 
cells, possibly by upregulating Runx1 transcription.79,26,81 BMP is supposed to be induced in 
those cells through Indian hedgehog (Ihh) signaling coming from the visceral endoderm.32,82 
On the other hand, there is rising evidence that BMP signaling plays a dual role in hematopoietic 
differentiation, in vitro at least; it has been shown Smad1 depletion before Flk1 expression limits 
the hematopoietic potential is limited due to a block in mesoderm development, but if Smad1 
depletion occurs after Flk1+ mesoderm commitment, the pool of hematopoietic progenitors is 
expanded.83,84 
Wnt signaling has been demonstrated to be essential during gastrulation, to the formation of 
the primitive streak.85,86,87 Wnt signaling is also implicated in this hematopoietic differentiation 
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process.88 It promotes differentiation towards blood fate through the activation of the Cdx-Hox 
genetic pathway: Cdx1 and Cdx4 are direct targets of the canonical Wnt pathway.89,90 Those 
genes in turn activate Hox genes such as HoxB4, which have been shown to be related to the 
expansion of the hematopoietic cell pool.79,91,92,93,94,95 What is more, Wnt and BMP signaling 
have been shown to cooperate in the specification of hematopoietic fate; BMP activates the Cdx-
Hox  pathway through the Wnt effector LEF1.46,79
In the presence of Wnt, binding of Wnt to its receptor, Frizzled (Fz), leads to the stabilization 
of  cytoplasmic β-catenin: Fz forms a complex with LRP5/6, and recruits Dishvelled (Dvl). Dvl 
phosphorylates LRP5/6, leading to the recruitment of Axin. This disrupts the phosphorylation/
degradation of β-catenin mediated by the Axin complex (Axin, APC, GSK3, and CK1). In turn 
β-catenin translocates to the nucleus, where it can activate the transcription of its target genes, after 
association with Lef/TCF transcription factors.  In the absence of Wnt, cytoplasmic β-catenin 
is sequestered by the Axin  complex. CK1, and subsequently GSK3, phosphorylate β-catenin 
and target it for proteosomal degradation upon recognition by the E3 ubiquitin ligase β-Trcp. 
Figure 5. General mechanism of TGF-β signaling pathway
At the cell surface, the ligand binds a complex of transmembrane receptor serine/threonine kinases (types I 
and II) and induces transphosphorylation of the type I receptor by the type II receptor kinases. The activated 
type I receptors phosphorylate R-smads then form a complex with Smad4. Activated Smad complexes 
translocate into the nucleus, where they regulate transcription of target genes, through physical interaction 
and functional cooperation with DNA- binding transcription factors. Activation of R-Smads by type I receptor 
kinases is inhibited by Smad6/7. The E3 ubiquitin ligases Smurf1/2 mediate ubiquitination and consequent 
degradation of R-Smads. LDN 193189 inhibits ALK-2, and -3, preventing phosphorylation, and activation of 
Smad1/5/8 (red arrow and box). Adapted from reference 72.
LDN 193189
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In the absence of β-catenin, Wnt target genes are repressed by the TCF-TLE/Groucho complex 
and Histone deacetylases (HDACs). CK1 also phosphorylate Axin and APC and enhance 
their binding to β-catenin and degradation complex stability. APC facilitates Axin degradation 
and possibly vice versa. PP1 dephosphorylates Axin to antagonize CK1 phosphorylation and 
TNKS
XAV939
C
Figure 6. General mechanism of the Wnt signaling pathway
A In the absence of Wnt, cytoplasmic β-catenin forms a complex with Axin, APC, GSK3 and CK1, and is 
phosphorylated by CK1, and subsequently by GSK3. Phosphorylated β-catenin is targeted for proteosomal 
degradation upon recognition by the E3 ubiquitin ligase β-Trcp. Wnt target genes are repressed by the 
TCF-TLE/Groucho complex and HDACs. B In the presence of Wnt ligand, a receptor complex forms 
between Fz and LRP5/6. Dvl recruitment by Fz leads to LRP5/6 phosphorylation, and Axin recruitment. 
This disrupts Axin-mediated phosphorylation/degradation of β-catenin, allowing β-catenin to accumulate 
in the nucleus where it serves as a co-activator for TCF to activate Wnt responsive-genes. C The core 
components of the Axin complex, Axin, APC, GSK3 and CK1 collectively promote β-catenin phosphorylation 
for degradation by β-Trcp. GSK3 and CK1 also phosphorylate Axin and APC and enhance their binding 
to β-catenin and degradation complex stability, further ensuring β-catenin phosphorylation. APC may also 
act to prevent PP2A dephosphorylation of β-catenin. APC facilitates Axin degradation and possibly vice 
versa. PP1 dephosphorylates Axin to antagonize CK1 phosphorylation and negatively regulates GSK3-Axin 
binding resulting in complex disassembly. Tankyrase (TNKS) destabilizes the Axin complex by stimulating its 
degradation through the ubiquitin proteasome pathway, thus promoting the activation of the Wnt-responsive 
genes. XAV939 inhibits TNKS, and thus stabilizes the Axin complex and inhibits Wnt-responsive gene 
activation. Adapted from reference 96.
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negatively regulates GSK3-Axin binding, resulting in complex disassembly. Tankyrase (TNKS) 
destabilizes the Axin complex by stimulating its degradation through the ubiquitin proteasome 
pathway, thus promoting the activation of the Wnt-responsive genes. 89,96 (Fig. 6) 
In the first part of this project, in order to better characterize the requirement for BMP and Wnt 
signaling in endothelial and hematopoietic differentiation, we used small molecule inhibitors 
to inhibit these two signaling pathways in an ES cell differentiation system modeling Flk1+ 
extraembryonic mesoderm, in serum free, layer free conditions.97,98,99 The data we accumulated 
indicates that although both BMP and Wnt signaling play a role in this differentiation process, 
none of them seems to be absolutely required to obtain endothelial and/or hematopoietic cells. 
Furthermore, our data partly reproduces what was observed in the Smad1 knockout experiment.84
Ets variant 2 (Etv2 also called ER71) is a transcription factor of the ETS family that has a non-
redundant and indispensable function in the regulation of blood and vessel development during 
mouse embryogenesis. It is expressed mainly in Flk1+ mesoderm and its derivatives. Etv2-/- mice 
are embryonically lethal; embryos die around E9.5 from failure to develop blood, vessels, and 
endocardium.46,100 In these embryos, no Flk1+ extraembryonic mesoderm could be detected. 
(Fig. 1) In Etv2-/- ESC cultures,  approximately the same phenotype was observed. (unpublished 
data) Thus showing that Etv2 is absolutely required for the formation of Flk1+ cells and for the 
development of blood and endothelial cells in embryos and in in vitro cultures. Etv2 expression 
is lost upon differentiation towards committed hematopoietic cell, or definitive endothelial cell 
fate. In zebrafish, Etv2 ortholog Ets-related protein (Etsrp) has been shown to be necessary for 
early embryonic vasculogenesis and hematopoieis.101 It functions downstream of a network 
combining BMP, Notch and Wnt signaling and regulates the expression of Flk1.32 Our hypothesis 
is that Etv2 switches on the GATA2/Fli1/Scl recursively wired gene-regulatory circuit during 
early hematopoietic development.78,102 This seems to be the case, as overexpression of either 
Scl or Fli1 in Etv2-/- ESCs can rescue these cell’s incapacity to differentiate into hematopoietic 
cells. (unpublished data)  In in vitro cultures, it has been shown, using inducible Etv2 ESCs that 
overexpression of Etv2 in ESCs leads to the induction of Flk1+ extraembryonic mesoderm-like 
cells.46 
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Tie2 (also called Tek) is a tyrosine receptor kinase that binds angiopoietins. Its expression starts 
at E7.5 in endothelial precursor cells, and angioblasts. Its expression is kept during development 
and throughout adulthood in virtually all endothelial cells.103,104,54,105 Hematopoietic precursor 
cells have been shown to express Tie2 as well, thus Tie2 expression spans the transition from 
angioblast to hemogenic endothelial cells.53,106 Tie2-/- mice die in utero from severe vascular 
defects, indicating that it is required for maintenance and organization of endothelial cells into a 
functional vasculature during development.107 It is thus a marker of choice for the study of pan-
endothelial processes during embryonic development.
To gain more insight on the in vivo importance of the spatial and temporal localization of the 
Etv2 signal during the early development. Overexpressing Etv2 in the Tie2 compartment, using 
a conditional knockout mouse, we were able to demonstrate that Etv2 expression is required 
to be transient; artificially maintaining Etv2 expression in the hematopoietic and endothelial 
compartments results in embryonic lethality at around E11.5.
3. Materials and Methods
Embryo generation
Mating of adult Tie2-CreWT/Tg males with Rosa26-etv2-IRES-GFPTg/Tg females was carried out 
overnight. Time-pregnant mice were killed by CO2 inhalation and uteri with embryos were 
removed by dissection. Pictures of the embryos were taken with a Keyence Biorevo inverted 
microscope. Contrast of the pictures was modified using Photoshop CS5 (Adobe).
PCR genotyping
Mice were genotyped using samples extracted either from embryo yolk sac or from adult 
mouse tail. The samples were lysed at 55°C with 200µg/mL ProK for 2-3h. Lysis was stopped 
by heat-inactivation at 95°C for 10min. PCR reaction mix included sample DNA 1:20, KOD-
Fx buffer (Toyobo), autoclaved MilliQ DEPC-treated H2O, dNTP mix (2mM each, Toyobo), 
KOD-Fx polymerase (Toyobo) and primers (ROSA26 locus: R1295: 5’-gcgaagagtttgtcctcaacc-3’, 
R523: 5’-ggagcgggagaaatggatatg-3’, R26F2: 5’-aaagtcgctctgagttgttat-3’; etv2GFP: Venus S11: 
5’-gtacaactacaacagccacaacgtc-3’, Venus AS11 5’-cacgaactccagcaggaccatgtg-3’; Tie2Cre: Cre Rev2: 
5’-agtgcgttcgaacgctagagcctg-3’, Tie2 5’F: 5’-gtgctcagacagaaatgagactg-3’). The reaction consisted 
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in 5 cycles at 58°C followed by 31 cycles at 56°C (33 cycles for embryo DNA samples). The 
reaction was carried out using a GeneAmp PCR System 9700 (AB). Reaction products were 
then mixed with loading buffer 1x (TaKaRa) and loaded on 2% agarose gels containing 0.5mg/
mL ethidium bromide. Gel-electrophoresis was performed (20min, 130V) and imaging was 
done with a printograph.
Cell culture
OP9 feeder layers were prepared in T25 or T75 culture flasks (Falcon), or 12-well tissue culture-
treated plates. OP9 cells were cultured in α-minimal essential medium (αMEM) (GIBCO) 
supplemented with 20% fetal calf serum (FCS) ( JRH, batch #3G0267). Every 3 days, OP9 
cells were dissociated by a 3min trypsin/EDTA 0.05% treatment at 37°C and split threeways. 
CCE mouse ES cells were maintained in knock-out Dulbecco’s modified Eagle’s medium (KO-
DMEM) (GIBCO) containing 15% FCS ( JRH, batch #4J0511), 1x non-essential amino acids 
(NEAA) (GIBCO), 2mM L-Glutamin (GIBCO), 10-4 M 2-mercaptoethanol (2-ME) and 
103 U/mL leukemia inhibitory factor (LIF) (Chemicon). CCE cells were seeded on gelatine 
(SIGMA)-coated 6cm tissue culture-treated dishes (Falcon) and were passaged every 2 days: 
after a 3min trypsin-mediated dissociation using trypsin/EDTA 0.25%, 2x105 cells were seeded 
on a new gelatine (SIGMA)-coated 6cm culture dish. OP9 and CCE cells were incubated at 
37°C, 5% CO2 and 95% humidity. OP9 and CCE cells were not cultured for more than 20 
passages. All mediums contained 50U/50µg/mL penicillin/streptavidin (Meiji). Pictures of the 
cell cultures were taken with a Leica DMI 4000B inverted microscope, and the Leica FIRECAM 
v3.3.1 software (Leica). Contrast of the pictures was modified using Photoshop CS5 (Adobe).
ES cell differentiation
To induce differentiation, CCE cells were seeded at density of 2400 cells/cm2 on confluent OP9 
feeder layers, in either T25 or T75 culture flasks, in αMEM containing 10% FCS (Multister, 
batch #C10031) and 5x10-5 M 2-ME, in the absence of LIF. They were then incubated at 37°C, 
5% CO2 and 95% humidity. After 4 days for ES cell differentiation, cultured cells were harvested: 
floating cells were collected, adherent cells were dissociated with a 3min trypsin/EDTA 0.05% 
(GIBCO) treatment, and replated for at least 30min to let the OP9 cells become adherent. The 
floating cells so-obtained were added to the ones collected in the first place. The harvested cells 
were left to recover in αMEM containing 10% FCS (Multister, batch #C10031) and 5x10-5 
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M 2-ME for 30 min before being stained and sorted. All mediums contained 50U/50µg/mL 
penicillin/streptavidin. Pictures of the cell cultures were taken with a Leica DMI 4000B inverted 
microscope, with the Leica FIRECAM v3.3.1 software (Leica). Contrast of the pictures was 
modified using Photoshop CS5 (Adobe).
Preparation of single cell suspensions from E10.5 embryos
Pregnant female mice were dissected 10.5 days post-coitum (dpc). Embryo proper and yolk 
sac were separated by dissection, and kept separated thereafter. They were washed in PBS and 
incubated 10min in trypsin/EDTA 0.05% at 37°C. Trypsinization was stopped with stop-solution 
(Hank’s balanced salt solution (HBSS) (GIBCO) containing 5mg/mL DNaseI (QIAGEN), 
20% FCS and CaCl2 10-4M), and the embryos were dissociated by pipetting. Finally, cells were 
resuspended in αMEM containing 10% FCS (Multister, batch #C10031) and 5x10-5 M 2-ME, 
and left to recover for 30 minutes at 37°C, 5% CO2 and 95% humidity.
Flow cytometry and cell sorting by Fluorescence-activated cell sorting (FACS)
Harvested differentiated ES cells were washed two times in Hank’s balanced salt solution 
(HBSS) (GIBCO) containing 1% bovine serum albumin (BSA, SIGMA), before being blocked 
in HBSS containing 1% BSA and 10% mouse serum for 30min at 4°C. Direct staining was 
achieved by incubation with Phycoerythrin (PE)- conjugated Flk1 (AVAS12a1, eBioscience) 
and Allophycocyanin (APC)-PDGFRα (CD140a) (APA5, eBioscience) monoclonal antibodies 
(MoAbs) for 15min on ice. The cells were washed three times with HBSS containing 1% BSA. 
Living Flk1+PDGFRα- cells were sorted and recultured in layer- and serum-free conditions. After 
4 days of culture, the cells were harvested and analyzed using the following conjugated MoAbs , 
using CD41-PE-Cy7 (eBioMWReg30, eBioscience), c-Kit (CD117)-PE (ACK2, eBioscience), 
CD11b-Fluorescein Isothiocyanate (FITC) (M1/70, BD), CD45-APC (30-F11, BD), CD45-
FITC (30-F11, eBioscience), CD105-eFluor 450 (MJ7/18, eBioscience), Tie2-PE (TEK4, 
eBioscience), VE-Cad-PE-Cy7 (VECD1, Biolegend), and Ter119-eFluor 450 (TER119, 
eBioscience). The staining was done using the same protocol as mentioned above.
Single cell suspension from embryos were stained and analyzed following the same protocol, 
with different combinations of conjugated MoAbs: VE-cad-PE-Cy7 (VECD1, Biolegend), 
CD45-APC (30-F11, BD), c-Kit-PE (ACK2, eBioscience), Tie2-PE (TEK4, eBioscience), and 
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CD41-PB (eBioMWReg30, eBioscience). The FITC channel was used to detect the GFP signal 
from the transgene.
The cells from the B-cell assay were stained following the same protocol, with a different 
combination of conjugated-MoAbs: B220 (CD45R)-APC (RA3-6B2, eBioscience), CD19-PE 
(1D3. BD), VE-Cad-PE-Cy7 (VECD1, Biolegend), c-Kit-PE (ACK2, eBioscience), and CD45-
APC (30-F11, BD).
In all FACS experiments, cells were gated to exclude small debris, dying cells and other sources 
of background interference and propidium iodide (PI)-gated to discard dead cells. These 
experiments were performed using a FACSAria II Special Order System (BD) with FACSDiva 
v6.1.3 software (BD). Data was analyzed using the FlowJo software v9.3 (Tree Star).
Cell reculture after FACS
Flk1+PDGFRα- cells were recultured in collagen-IV-coated 6-well plates (BD Biocoat) or in 
collagen-I-coated 4-well culture-slides (BD Biocoat), at a density of 3.125x104 cells/cm2, in 
SFO3 medium (Sankojunyaku) containing 5x10-5 M 2-ME, 100π/mL mouse Interleukin (mIL)-
3 (purified in the lab), 100ng/mL granulocyte-colony-stimulating factor (G-CSF, Kirin), 100ng/
mL stem cell factor (SCF, purified in the lab), and 100ng/mL recombinant human Erythropoietin 
(rhEPO, PROSPEC) or 10ng/mL recombinant mouse Erythropoietin (rmEPO, R&D). Cells 
were cultured in the presence or absence of BMP signaling inhibitor LDN-193189 (Stemgent), 
Wnt signaling inhibitor XAV-939 (Tocris), in duplicate. After 4 days incubation at 37°C, 5% CO2 
and 95% humidity,cells were harvested and analyzed by flow cytometry, or immunostained for 
fluorescence imaging.
VE-Cad+CD45+ cells isolated from E10.5 embryos were recultured on tissue culture-coated 12-
well plates containing a confluent OP9 feeder layer, 500 cells/well, in 1mL of  αMEM containing 
10% FCS ( JRH, batch #3G0267), 5x10-5 M 2-ME, 10ng/mL Flt3l (), 10ng/mL mIL-7 (), 
and 20ng/mL SCF. After 7 days incubation at 37°C, 5% CO2 and 95% humidity, 1mL of the 
same medium, without the SCF was added to each culture well. On day 14 or 15, the cells were 
harvested following the same protocol as for the ES cell differentiation, and analyzed by flow 
cytometry.
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All mediums contained 50U/50µg/mL penicillin/streptavidin.
Colony-forming unit (CFU) assay
Sorted VE-Cad+CD45+ cells isolated from E10.5 embryos were used in this assay. Cells were 
resuspended in αMEM containing 10% FCS ( JRH, batch #3G0267) and 5x10-5 M 2-ME, at a 
concentration of 500 cells/100µL. 2000 cells were then mixed together with 4mL MethoCult 
GF M3434 (STEMCELL technologies) by vortexing. The tube was then left to rest for 5 minutes 
to allow bubbles to dissipate. 1.1mL of this cell suspension was dispensed in a 35mm Petri dish 
(Falcon). Each assay was done in triplicate. The three Petri dishes, plus a fourth one filled with 
sterile water, were kept in a square bacterial box  for 8 days at 37°C, 5% CO2 and 95% humidity. 
Burst-forming unit-erythroid (BFU-E), CFU-granulocyte (G), CFU-macrophage (M), CFU-
granuolcyte, macrophage (GM), and CFU-granulocyte, erythroid, macrophage, megakaryocyte 
(GEMM) were counted on day 8. Pictures of the colonies were taken with a Leica DMI 4000B 
inverted microscope, with the Leica FIRECAM v3.3.1 software (Leica). Contrast of the pictures 
was modified using Photoshop CS5 (Adobe).
Immunostaining
After 4 days, Flk1+PDGFRα- cells recultured on Collagen-I-coated 4-well culture slides were 
immunostained. Adherent cells were fixed in ice-cold methanol for 8min on ice. They were 
rehydrated through the ethanol serie (70%, 50% and 25%) and washed with phosphate-buffered 
saline (PBS). Blocking was achieved through incubation in PBS containing 2% skim milk 
(GIBCO) and 0.1% Tween 20 (Nacalai Tesque) (PBS-MT) 30min at room temperature (RT). 
The fixed wells were incubated with goat anti-ICAM2 (1/500, R&D),  and rat anti-PECAM-1 
(1/500, 390, BD) MoAbs overnight, on shake at 4°C. The wells were then incubated with Alexa-
488-conjugated donkey anti-rat-IgG (1/500, Invitrogen) and Alexa-546-conjugated donkey 
anti-goat-IgG (1/500, Invitrogen)MoAbs overnight, on shake at 4°C. After each step, cultured 
cells were washed 3 times with PBS-MT. Finally, they were rinsed twice with PBS containing 
0.1% Tween 20, and pictures were taken with a Keyence Biorevo BZ 9000 inverted microscope, 
with the manufacturer’s software, BZ II (Keyence). Contrast of the pictures was modified using 
Photoshop CS5 (Adobe). Image overlays were done with the BZII software (Keyence).
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The same protocol was applied to E9.5 mouse embryos, in a 24-well plate, except that the blocking 
was carried out for 6h on ice, and that the secondary antibody was incubated for 1h30min at 
RT, on shake. Primary antibody: goat anti-Flk1 MoAb (1/500, R&D), secondary antibody: 
Alexa546-conjugated donkey anti-goat-IgG MoAb (1/500, Invitrogen) .
RNA extraction
RNA was extracted using QIAGEN’s RNeasy Micro Kit, following the manufacturer’s protocol 
(Total RNA purification from animal or human cells, RNeasy MicroHandbook, 2nd edition, 
12.2007). For the Flk1+ recultured cells, RNA was extracted from 105 cells, for the microarray 
analysis from E10.5 VE-Cad+CD45+ cells, a few thousand cells were used in each reaction. In 
every case, cells were homogenized by one minute vortexing after resuspension in RLT buffer 
(QIAGEN).
Quantitative reverse transcriptase-PCR (qRT-PCR)
Reverse transcription was carried out using Toyobo’s ReverTra Ace qPCR RT Kit, following the 
manufacturer’s protocol. 50ng RNA was used for each reaction. Real-time PCR was performed 
in 25µL reactions consisting of 12.5µL Power SYBR Green PCR Master Mix (2x) (AB), 2.5µL 
primer mix (2µM each, Hokkaido System Science), and 100ng or 50ng of cDNA diluted in 
10µL MilliQ DEPC-treated H2O. Transcript levels were assessed using the 7500 Real Time PCR 
System (AB). The thermocycling conditions used were 2min at 50°C, 10min at 95°C, followed by 
40 cycles of 15sec at 95°C, 1min at  60°C. At the end of the run, a thermal dissociation stage was 
added to assess the specificity of the polymerase reaction: 2 cycles of 15sec at 95°C, and 1min 
at 60°C. Data acquisition was done with the 7500 System Software (AB). Each experiment was 
done in triplicate. Gene expression analysis was performed using the Relative Standard Curve 
Method, using the housekeeping gene GAPDH for normalization.
Gene Forward (5'-3') Reverse (5'-3')
Runx1 CCAGGTAGCGAGATTCAACGA CAACTTGTGGCGGATTTGTAAA
Gata2 GGCGTCAAGTACCAAGTGTCAC CTCCCGGCCTTCTGAGCAGGAG
Fli1 TGCTGTTGTCGCACCTCAGTTA TGTTCTTGCCCATGGTCTGTG
Scl CAGCCTGATGCTAAGGCAAG AGCCAACCTACCATGCACAC
Lyl1 CAGGACCCTTCAGCATCTTC ACGGCTGTTGGTGAACACTC
Lmo2 TCAGCTGTGACCTCTGTGG CACCCGCATCGTCATCTC
PU.1 TGTTACAGGCGTGCAAAATG TCATGCATTGGACGTTGGTA
Erg GGAGTGCAACCCTAGTCAGG TAGCTGCCGTAGCTCATCC
Myb AACGAGCTGAAGGGACAGCA TGGCATGGTGTTCTCCCAAA
Gata1 AATCCTCTGCATCAACAAGC GGAAGTGGAAGAAGATGCTG
Klf1 CCCTCCATCAGTACACTCACC AGGGTCCTCCGATTTCAGAC
Sox17 CAGAACCCAGATCTGCACAA GCTTCTCTGCCAAGGTCAAC
Table 1. qRT-PCR primer sequences
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Microarray analysis
Microarray analysis was performed by the Genome Resource and Analysis Subunit of  RIKEN 
CDB. At least 10ng of starting RNA were used for each sample. SurePrint G3 Gene Expression 
Microarrays - 8x60K (Agilent) were used. After scanning, digitalization was made with Feature 
Extraction10.7.3.1, and the data was analyzed using GeneSpring GX 11.5.1. The expression 
levels were first normalized, then the values for the Cre+ samples were averaged, and compared 
to  the value for the Cre- control.
Statistics
Statistical analysis on the flow cytometry analysis data was performed using both regular and 
Bonferroni-corrected double-tailed, paired Student’s t-test. Results were considered significant 
when p-value<0.05.108
4. Results
Effects of BMP and Wnt signaling inhibition on the differentiation of a Flk1+ extraembryonic mesoderm 
in vitro model
It has been shown that BMP signaling, and Wnt signaling have an enhancing role at various 
time points of the differentiation process towards hematopoietic and endothelial fates, through 
the action of BMP4, and Wnt3a particularly.74,76,79,82,85,88,89,90,91 In order to better characterize the 
requirement for BMP and Wnt signaling in the transition of Flk1+ extraembryonic mesoderm 
towards endothelial and endothelial lineages, we used small molecule inhibitors to inhibit these 
two signaling pathways in an ES cell differentiation system modeling Flk1+ extraembryonic 
mesoderm, in serum-free, feeder cell layer-free conditions. To obtain Flk1+PDGFRα- cells, we 
differentiated CCE mouse ES cells in serum-containing medium, on confluent OP9 feeder 
layers, for 4 days. The cells were then sorted by FACS and subsequently recultured in Collagen-
IV-coated 6-well plates, in SFO3, a serum-free, chemically defined culture medium that was 
shown to support endothelial, and hematopoietic differentiation in a similar system.109 The 
medium contained a combination hemopoietic factors: VEGF, EPO, IL-3 , G-CSF, and SCF, 
in the presence or absence of BMP signaling inhibitor LDN-193189 (called LDN thereafter), 
and/or canonical Wnt signaling inhibitor XAV939 (called XAV thereafter). “Wnt signaling” will 
thereafter mean only the canonical Wnt pathway, since the non-canonical ones are supposably 
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unaffected by XAV939. LDN inhibits BMP Type I receptors ALK-2, and ALK-3, preventing 
phosphorylation, and subsequent activation of Smad1/5/8, thus shutting down BMP signaling.110 
XAV inhibits TNKS, and thus stabilizes the Axin complex and inhibits Wnt-responsive gene 
activation.111 After 4 days of culture, cells were harvested, and analyzed. (Fig. 7A-C)
After reculture on Collagen-IV, differences were visible by simple microscope observation: by 
day 2, the wells that contained the the BMP signaling inhibitor displayed hindered hematopoietic 
differentiation, and bigger, easier to see endothelial structures. At day 4 of differentiation, these 
differences could still be seen, although they were less obvious, probably because, by then, the 
cells looked a little less healthy. (Fig. 7D) The overall cell number that was retrieved from each 
duplicate was about the same in all conditions, although a statistically relevant 30% decrease was 
observed in the wells that contained both inhibitors. (Fig. 8) This probably reflects the reduced 
amount of hematopoietic cells that were retrieved from these wells, and not a in viability, and/
or proliferation potential.
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Figure 7. The differentiation system
A Model of the differentiation system used in this study. CCE cells were seeded on OP9 feeder layers, and 
differentiated for 4 days in serum-containing medium. Flk1+PDGFRα- cells were sorted and recultured in 
Collagen-IV-coated 6-well plates, in serum-free medium containing hemopoietic factors, in the presence 
or absence of LDN 193189 (400nM), and/or XAV939 (200nM). 4 days later, the cells were harvested and 
analyzed. B Colonies of undifferentiated CCE mouse ES cells before they were seeded. Phase contrast 
microscopy, 100x, scale bar = 100µm.. C Typical structure obtained after 4 days differentiation of CCE cells 
in serum-containing medium on OP9 feeder layer. Phase contrast microscopy, 100x, scale bar = 100µm. 
D Typical aspect of the cultures after 2, or 4 days of differentiation on Collagen-IV, using the differentiation 
system from A. Phase contrast microscopy, 50x, scale bar = 100µm.
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We first wanted to observe how the fate of these cells was affected by the addition of the small 
molecule inhibitors. We  thus checked  the expression of endothelial and hematopoietic markers 
by flow cytometry analysis. The effect of the inhibitors was evident, and reproducible (n=6, or 
7). BMP and Wnt signaling inhibition appears to work synergistically to restrict differentiation 
towards pre-HSC-like cells, defined by coexpression of VE-Cad and CD45: used separetly, 
LDN and XAV had a similar effect; they lowered the number of these cells almost 2x. When 
both inhibitors were used together, the potential to give rise to VE-CAd+CD45+ cells was 
lowered by about 4x. (Fig. 9A) A similar pattern, was observed for early hematopoietic cells 
(CD41+CD45-), further committed hematopoietic cells (CD41-CD45+), and macrophage 
progenitor cells (CD45+CD11b+): LDN and XAV deplete these cell pools by a factor 1.4, 1.9, 
and 1.7 respectively, and their effect appears to be cumulative, as these factors are approximately 
doubled when both small molecule inhibitors are used together: factor 2.3, 3.4, and 4.25, 
respectively. (Fig. 9E-F) This is consistent with the previous idea that BMP and Wnt signaling 
cooperate in the specification of hematopoietic fate. Hematopoietic progenitor cell (CD45+c-
Kit+) number follows a slightly different pattern: although the depletion of this cell pool is higher 
when both BMP and Wnt signaling are inhibited, by a factor 2, LDN alone does not display 
any striking depleting effect, when XAV does (by a factor 1.45). (Fig. 9D) This data indicates 
that hematopoietic differentiation is restricted when  BMP and Wnt signaling are suppressed. 
Suprisingly, the early hematopoietic progenitor cells pool (CD41+c-Kit+), however, is relatively 
unaffected by both inhibitors. (Fig. 9C) 
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Figure 8. Cellularity is only slightly affected by LDN 193189 and XAV939
Number of cells retrieved per duplicate after reculture of Flk1+PDGFRα- on Collgen-
IV for 4 days in serum-free medium containing hemopoietic factors, in the presence 
or absence of LDN 193189 (400nM), and/or XAV939 (200nM) The left bar plot shows 
the absolute cell count. The right bar plot represent cell number, normalized, for each 
experiment, to the mean of the experiment, to dampen starting cells proliferation 
potential-related variations. n=7, error bars: ±SEM, *: p-value<0.05/13
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Figure 9. Inhibition of BMP and/or Wnt signaling alters the hematopoietic potential
Flow cytometry analysis of Flk1+PDGFRα- cells after 4 days of differentiation on Collagen-IV, in serum-
free medium containing hemogenic factors. The red plots display only Ter119- cells. The bar plots on the 
right represent the percentage of cells expressing the indicated markers, multiplied by cell number, then 
normalized, for each experiment, to the mean of the experiment. n=7, error bars: ±SEM, *: p-value<0.05/13
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LDN 193189 significantly expanded about 2x the  proerythroblast pool, defined as Ter119lowc-
Kit+. Even though Wnt signaling was supposed to be required for the commitment to the primitive 
erythroid lineage,59 XAV939 did not decrease the proerythroblast pool. However, 
when both inhibitors were added together, the promoting effect of the BMP signaling inhibition 
seemed to be slightly dampened. (Fig. 9B) This erythroid cell pool was in our differentiation 
system the only hematopoietic compartment to be affected by BMP signaling in a manner that 
reproduces the observations made by the group of Todd Evans84 with the Smad1 Tet-off system. 
This discrepancy might be the result of the different system that were used, as we performed 
this experiment on adherent cell cultures, when they used embryoid bodies. It could also be 
that Smad1 inhibition has a different effect than LDN-based suppression of the BMP signaling 
pathway.
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Figure 10. BMP signaling inhibition expands the endothelial compartment
Flow cytometry analysis of Flk1+PDGFRα- cells after 4 days of differentiation on collagen-IV, in serum-free 
medium containing hemogenic factors, in the presence or absence of LDN 193189 (400nM), and/or XAV939 
(200nM). The bar plots on the right represent the percentage of cells expressing the indicated markers, 
multiplied by cell number, then normalized, for each experiment, to the mean of the experiment. Each 
experiment was done in duplicate, n=7, error bars: ±SEM, *: p-value<0.05/13
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Flk1 expressing cell number was virtually unaffected by LDN, XAV, or even a combination of both 
inhibitors. (Fig. 10A) Other endothelial cell pools (CD105+Tie2+, and Tie2+VE-Cad+),112,113 
on the other hand, were clearly expanded by a factor 2 when LDN was used alone, the effect
of XAV used alone, and of both inhibitors toegether are less obvious, but seem consistent: 
reduction, and expansion, respectively, both by a factor 1.3. (Fig. 11B-C). The expansion of 
the endothelial compartment by LDN was quite a surprise, as Gata2, one of the genes driving 
endothelial differentiation is activated by BMP signaling.117 The reason for that might be that, 
since hematopoietic differentiation is blocked, more cells keep an endothelial phenotype. 
Flk1+PDGFRα- cells were also cultured on Collagen-I-coated glass culture slides, with the 
same serum-free medium and factors combination. The differentiation pattern was apparently 
identical to the one obtained with collagen-IV-coated well plates. In these cultures, similar effects 
of BMP and Wnt signaling on the differentiation towards the endothelial lineage were observed 
by immunostaining for Platelet endothelial cella adhesion molecule (PECAM-1, also known as 
CD31), and Intercellular cell adhesion molecule (ICAM2), two pan-endothelial markers.114,115 
In the wells containing LDN, the endothelial structures were clearly bigger. Furthermore, they 
looked to be the biggest when LDN was used alone. The flow cytometry data obtained for the 
endothelial lineage was thus confirmed by immunostaining. (Fig. 11) 
To better understand the molecular mechanisms behind the effects of BMP and Wnt signaling 
inhibition on endothelial, and hematopoietic differentiation, we carried out qRT-PCR 
experiments. Flk1+PDGFRα- cells were harvested after 4 days reculture on Collagen-IV, and 
their  total RNA was extracted. It was reverse-transcribed to cDNA, and qPCRs were performed. 
We targeted genes that are implicated in the transcriptional network that drives endothelial and 
hematopoietic differentiation program. Genes implicated in early events of this differentiation 
process, such as Runx1, Fli1, Scl, Lyl1, and Myb116 expression followed a similar pattern: LDN, 
or XAV, alone did not significantly change the level of expression. When both inhibitors were 
added together, a small but remarkable increase in expression could be observed (1.26x, 1.21x, 
1.58x, 1.41x, and 1.75x respectively). This pattern looks inversely proportional to the effect of 
the inhibitors on hematopoietic differentiation. Gata2, Lmo2, and Erg,116 on the other hand are 
affected in a different manner by BMP and Wnt signaling inhibition. Gata2 was downregulated 
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Figure 11. Endothelial structures are bigger in the LDN 193189-containing wells
Staining was done after the Flk1+PDGFRα- were recultured for 4 days on Collagen-IV. Green: 
PECAM-1, red: ICAM2. Fluorescence microscopy, 40x, scale bar: 100µm, n=2.
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by LDN alone (0.67x), as expected since it is a direct target of BMP4.117 Unexpectedly, if both 
inhibitors were added together, this downregulating effect of LDN on Gata2 expression was 
lost. However, XAV alone did not provoke any remarkable change in Gata2 expression. Lmo2 
was unaffected by both inhibitors, which was rather surprising, as we expected it to follow a 
pattern similar to his interaction partners Scl and Lyl1.116 Erg was significantly upregulated by 
BMP signaling expression (LDN only: 3.95x, LDN and XAV: 3.61x), but unaffected by Wnt 
signaling inhibition. This seems to reflect its importance in the endothelial differentiation 
process.118 Suprisingly, the hematopoietic-specific transcription factor PU.1119 was unaffected 
by both small molecule inhibitors. Gata1, on the other hand was clearly upregulated by 
both LDN and XAV (LDN only: 2.3x, XAV only: 5.6x, LDN + XAV: 3.6x). This increase in 
Gata1 expression is consistent with the expansion of the proerythroblast pool in the LDN-
containing wells, as Gata1 is the key transcription factor of erythroid differentiation.120 
However, in the well where only Wnt signaling was inhibited, Gata1 upregulation is evident, 
but there was no increase in the erythroid cell pool. This tends to indicate that even though 
Gata1 is required to obtain erythroid cells, its expression level is not directly linked to the 
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Figure 12. Differences in expression levels of key endothelial and hematopoietic trancription factors
Expression levels of key endothelial and hematopoietic transcription factors were assessed by qRT-PCR. 
Total RNA was extracted  from  Flk1+PDGFRα- cells recultured 4 days on Collagen-IV in serum-free medium 
containing hemopoietic factors, in the presence or absence of LDN 193189 (400nM), and/or XAV939 
(200nM). Raw data was obtained using the Relative Standard Curve Method. It was then normalized using 
GAPDH as a reference. The bar plot represents fold changes relative to control. Each experiment was done 
in triplicate, n=4, error bars: ±SEM.
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size of this cell pool. Finally, the definitive endothelial transcription factor Sox17 was as well 
upregulated only in the wells that contained LDN (LDN only: 2.56x, LDN + XAV: 2.48), 
which is consistent with the expansion of the endothelial cell pool in those wells. XAV only-
continaing wells seem to have a slightly downregulated expression of Sox17 (0.62x). (Fig. 12)
The fact that the changes in gene expression are not as evident as the differences observed by 
flow cytometry analysis might be due to the fact that we performed the qRT-PCRs at day 4 of 
differentiation on Collagen-IV. The data might thus reflect more the result of the LDN and XAV 
signaling on the differentiation pattern than their effects on the transcription network itself. 
To obtain more information on that latter matter, we should perform again the same reactions, 
but after only 1 day of differentiation on collagen-IV, or in sorted populations after 4 days of 
differentiation. Furthermore, data analysis was made difficult for some of those genes, as  their 
expression levels are very low, namely Erg, Myb, Gata1, and Sox17. This made the results quite 
variable, as indicated by the high standard error of the mean. (Fig. 12)
Expansion of a VE-Cad+CD45+ population in the yolk sac upon Etv2 overexpression in mouse embryo
Etv2 is one of the earliest markers of differentiation towards endothelial, and hematopoietic 
lineages in the mouse embryo. In zebrafish, its ortholog Etsrp is both necessary and sufficient to 
initiate vasculogenesis.101 Etv2 is turned on before Flk1 expression, and it is expressed in the same 
region, the extraembryonic mesoderm. The Etv2-/- mutation is embryonically lethal.Embryos 
die around E9.5 from failure to develop blood, vessels, and endocardium.46,100 Etv2 expression 
is very transient: as soon as the Etv2+ cells commit to either endothelial, or hematopoietic fates, 
they lose its expression. To gain more insight on the spatial and temporal localization requisite 
expression pattern of Etv2, Dr. Hiroshi Kataoka developed a CAG promoter-controlled Etv2-
IRES-GFP construct containing a floxed stop-cassette, and inserted it within the ROSA26 locus. 
This mouse line could then be crossed with various Cre-recombinase (Cre) mouse line to allow 
the tissue-specific expression of the transgene.121 
It was previsously shown by Dr. Kataoka that overexpressing Etv2 in the Vav,122 and Sox17123 
compartments, that represent more definitive hematopoietic, and endothelial cells, respectively, 
does not affect embryonic development, and that these mice develop normally until adulthood 
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, although they seem to have a shorter life expectancy. (unpublished data) He also showed, 
however, that overexpressing Etv2 in the MesP1 compartment (early mesoderm),124 is 
embryonically lethal. These embryos die around E11.5. They present a bleeding phenotype, and 
some abnormal structures in the yolk sac vasculature at this stage. (unpublished data) Continuing 
in the same direction Dr. Kataoka crossed Tie2CreWT/Tg and Rosa26-etv2-IRES-GFPTg/Tg mice in 
order to overexpress Etv2 in the whole endothelial compartment.105 (Fig. 14A) He obtained 
data indicating that these embryos die also around E11.5 and that they are a phenocopy of the 
Mesp1CreWT/TgRosa26-etv2-IRES-GFPTg/WT embryos. (unpublished data, Fig. 13)
We then further investigated on the mechanisms that allow Etv2 overexpression to lead to the 
death in utero of the Tie2CreWT/TgRosa26-etv2-IRES-GFPTg/WT embryos (referred to Cre+ embryos 
thereafter). We confirmed that the embryos are viable until E10.5, at which stage the proportion 
of live embryos is close to the Mendelian ratio : 38% for E9.5, and 49% for E10.5. This proportion 
Cre- Cre+A
Cre- Cre+B PECAM-1
C Cre+
PECAM-1 PECAM-1
Figure 13. At E11.5, Tie2CreWT/TgRosa26-etv2-IRES-GFPTg/WT embryos present a bleeding phenotype, 
and some abnormalities in the yolk sac vasculature
A E11.5 embryos, lateral view, the bleeding phenotype is evident in the Cre+ embryo. B E11.5 yolk sacs. 
PECAM-1 immunohistochemistry staining. White arrow:  abnormal vascular structure in the Cre+ yolk sac. 
C Detail of an abnormal vascular structure in a E11.5 Cre+ yolk sac. Cre-: Tie2CreWT/WTRosa26-etv2-IRES-
GFPTg/WT embryos, Cre+: Tie2CreWT/TgRosa26-etv2-IRES-GFPTg/WT embryos. Courtesy of Dr. Hiroshi Kataoka
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drops to 10% only for live born pups. (Table 2) The fact that we still obtain live pups that look 
normal (at least  until 2 weeks after birth) indicates there is an escape mechanism that allow 
embryos to survive in spite of the transgene’s presence. It is possible that the transgene-expressing 
cells are rapidly counter-selected during development: As Cre-recombination does not have a 
penetrance of 100%,125 it is possible that the transgene-expressing cells are excluded from the 
endothelial, and/or hematopoietic compartment of the surviving embryos. This will have to be 
tested in the future as we didn’t have enough time to perform this assay before the deadline for 
this report.
At E9.5, the Cre+ embryos did not display any gross vasculature defect, as assessed by Flk1 
immunostaining. (Fig. 14B) The localization of the transgene-expressing cells in the Cre+ 
embryos was determined, taking advantage of the GFP reporter integrated in the construct. In 
the E10.5 embryo proper, these cells localized as expected in the vascular endothelium. (Fig. 
14C) In the yolk sac, though, the Cre+ embryos displayed a clear typical pattern: the GFP+ cells 
formed small clusters, that recall the abnormal vascular structures found in the yolk sac of these 
embryos at E11.5. (Fig. 14D-E) This pattern of transgene expression was also observed in E9.5 
yolk sacs (data not shown). However, it was not present on all E9.5 and E10.5 yolk sacs, and 
absent in all the E14.5 yolk sacs, (Table 2) further supporting the idea that there is a mechanism 
that allows some embryos to exclude transgene-expressing cells from the endothelial, and/or 
hematopoietic compartments in order to survive. The expression level of the transgene was 
not particularly high, which implies that the imaging probably does not show all the transgene-
expressing cells.
In order to characterize the cell population that formed those clusters in the E10.5 yolk sacs of 
the Cre+ embryos, E10.5 embryo propers and yolk sacs were separated by dissection, dissociated 
into a single cell suspension, and analyzed by flow cytometry for their expression of several 
endothelial, and hematopoietic markers. Flow cytometry analysis also allowed us to assess with 
Stage
Total # of 
embryos
Cre- Cre+
Cre+ with YS 
GFP pattern
Cre+/Total 
ratio
E9.5 29 18 11 4 0.38
E10.5 45 23 22 19 0.49
E14.5 5 2 3 0 0.6
P0 20 18 2 0 0.1
Table 1. Analysis of progeny of Tie2CreWT/Tg and Rosa26-etv2-IRES-GFPTg/Tg intercrosses
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more certainty which embryos were Cre+, and which were Cre-, when the diagnosis was uncertain, 
by checking for GFP expression. In the embryo proper, there was no change in the number of 
VE-Cad+ cells, and surprisingly a 2-fold reduction in the number of CD45+ and VE-Cad+CD45+ 
cells. (Fig. 15 & 16) In the yolk sac tissue, all three CD45+, VE-Cad+, and VE-Cad+CD45+ 
populations approximately doubled in cell number in the Cre+ embryos (2.51x, 2.22x, and 2.7x, 
respectively). (Fig. 15 & 16) The fact that this VE-Cad, and CD45 double-positive cell pool 
was expanded more than 2 times in the Cre+ embryos was very intriguing, as theses cells are 
neo etv2 IRES GFPSTOP
cre-recombinaseTie2 promoter
 
CAG Promoter pA
pA
etv2 IRES GFP
 
pA
Cre-recombination
A
CAG Promoter
Cre- Cre+
Flk1 Flk1
B
Cre- Cre+
Tie2Cre-ROSAGFP
C
Tie2Cre-ROSAGFP
C
re
-
C
re
+
Tie2Cre-ROSAGFP
D
Tie2Cre-ROSAGFP
Cre- Cre+E
Tie2Cre-ROSAGFP Tie2Cre-ROSAGFP
Figure 14. Transgene-expressing cells locate in the vasculature endothelium and form clusters on 
the yolk sac at E10.5
A The Tie2Cre construct, and the Rosa26-etv2-IRES-GFP construct, before and after Cre-recombination.
B E9.5 vasculature (lateral view), immunostaining for Flk1. Fluorescence microscopy, 40x, scale bar=100µm. 
C Localization of the transgene-expressing cells in the E10.5 embryo proper (lateral view). Fluorescence 
microscopy, 40x, scale bar=100µm. Insert: transgene-expressing cells located in the intersomite vasculature 
(dorsal view). Fluorescence microscopy, 100x, scale bar=100µm. D,E Typical localization pattern, in clusters, 
of the transgene-expressing cells in E10.5 yolk sacs. Fluorescence microscopy, 40x, scale bar=100µm. Cre-: 
Tie2CreWT/WTRosa26-etv2-IRES-GFPTg/WT embryos, Cre+: Tie2CreWT/TgRosa26-etv2-IRES-GFPTg/WT embryos.
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thought to represent pre-definitive-HSC-like cells. 66,126 Furthermore, we noticed that more 
than 90% of the VE-Cad+CD45+  found in the Cre+ embryos expressed the transgene. Most 
of them were also expressing c-Kit and CD41, when it was not the case for their counterparts 
in the Cre- embryos,. (Fig. 15) There was thus an expansion of a population of immature 
hematopoietic cells upon overexpression of Etv2 in the E10.5 yolk sac in endothelial cells.
These observations pushed to attempt to characterize better this VE-Cad+CD45+ population. 
We thus sorted these cells by FACS from E10.5 yolk sacs, and used them to perform a CFU 
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Figure 15. Expansion of a VE-Cad+CD45+ population in the E10.5 yolk sac of Cre+ embryos
Flow cytometry analysis plots from two representative experiments. Embryo propers and yolk sacs were 
separated by dissection, dissociated into single-cell suspensions, and analyzed separately. Cre-: Tie2CreWT/
WTRosa26-etv2-IRES-GFPTg/WT embryos, Cre+: Tie2CreWT/TgRosa26-etv2-IRES-GFPTg/WT embryos.
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Figure 16. Summary of the flow cytometry analysis data from E10.5 embryo 
propers and yolk sacs
Flow cytometry analaysis data. The gating that was used is showed in Fig. 15. 
Embryo propers and yolk sacs were separated by dissection, dissociated into 
single-cell suspensions, and analyzed separately. n=3, error bars: ±SEM. EP: 
embryo proper, YS: yolk sac, Cre-: Tie2CreWT/WTRosa26-etv2-IRES-GFPTg/WT 
embryos, Cre+: Tie2CreWT/TgRosa26-etv2-IRES-GFPTg/WT embryos.
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methylcellulose assay, a microarray analysis, and a B-cell assay. (Fig. 17) This was done aiming 
to determine the hematopoietic potential of these cells, and to obtain more insight on the 
downstream targets of Etv2. However, due to the small amount of time and the difficulty to obtain 
big numbers of these cells, these experiments were done only once, and need to be reproduced at 
least two more times to gain statistical significance.
In the CFU-assay, 500 VE-Cad+CD45+ cells were seeded per dish, and colonies were counted 8 
days later. In the dishes seeded with cells coming from Cre+ yolk sacs, all sorts of colony-forming 
units were observed: BFU-E, CFU-G, CFU-M, CFU-GM, and CFU-GEMM. (Fig. 18) We 
obtained an average of 61 colonies/500 cells seeded, which provides us with strong evidence 
that these cells have at least erythroid, and myeloid potential. For the Cre- control, as we were 
not able to obtain enough cells, from the Cre- yolk sacs, we had to sort the same population 
from wild type BL6 mice. In this control, in all  three dishes of the triplicate, only 2 colonies 
were observed (2 CFU-GEMM). This latter result is hard to believe and is probably due to an 
unidentified technical problem. Unfortunately, there was no time to do this experiment one more 
time. Although the seeded cells were visible in the medium all along, they did not proliferate. The 
same cells generate large amounts of hematopoietic cells when seeded on an OP9 feeder layer 
for the B-cell assay.
The microarray analysis was performed using the new generation of arrays from Agilent, that 
allow the use of amounts of RNA as low as 10ng. Nevertheless, even in these conditions, it was 
VE
-C
ad
he
rin
CD45
VE
-C
ad
he
rin
CD45 ROSA-GFP
FACS
FACS
ROSA-GFP
CFU-A
OP9
B-cell assay
Microarray analysisC
re
-
C
re
+
Figure 17. Sorting of VE-Cad+CD45+ cells from E10.5 yolk sacs and experimental plan
Ve-Cad+CD45+ cells from dissociated E10.5 yolk sacs were sorted following this plan. These cells were 
subsequently used for CFU-assay, microarray analysis, and B-cell assay. Cre-: Tie2CreWT/WTRosa26-etv2-
IRES-GFPTg/WT embryos, Cre+: Tie2CreWT/TgRosa26-etv2-IRES-GFPTg/WT embryos.
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extremely difficult to obtain the 10’000 cells needed for each array, and we had to adapt our 
methodology according to this matter. In the end, two array experiments, with Cre+ samples 
coming from 2 different litters were performed. For the Cre- control, however, VE-Cad+CD45+ 
cells coming from 3 different litters had to be combined to obtain enough RNA for a single 
microarray. Finally, the expression levels of the two Cre+ samples were average and compared to 
the single control. The statistical significance of these results is thus low, and we were unable to 
look for precedently uncharacterized potential targets of Etv2 in mouse. 
Even though the experimental conditions were not optimal, the data accumulated from this 
experiment is rather sensible: a number of genes previously identified as being targets of Etv2 in 
similar experiments performed in zebrafish127,128 were found to be upregulated in our system as 
well. Furthermore, there was a enrichment for endothelial-related genes in the most upregulated 
genes, and the major part of the key transcription factors linked to endothelial and hematopoietic 
differentiation were found to be at least slightly upregulated upon Etv2 overexpression. 
The most 50 most upregulated are presented in Tables 3, amongst them, Etv2 (13.95x) indicates 
that the transgene is working correctly. VE-Cad (11.4x), and Flk1 (10.26x), two direct targets 
of Etv2,127,128 provide some evidence that the experiment is at least accurate to some extent. 
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Figure 18. VE-Cad+CD45+ cells sorted from E10.5 Cre+ yolk sacs have erythroid and myeloid potential
Sorted Ve-Cad+CD45+ cells from E10.5 Cre+ yolk sacs were used to perform a CFU-assay. The assay was 
done in triplicate, 500 cells were seeded per dish, n=1. A Summary of the number of colonies per dish. 
B Typical aspect of BFU-E, CFU-G, CFU-M, and CFU-GEMM. Phase microscopy, 50x. Cre-: Tie2CreWT/
WTRosa26-etv2-IRES-GFPTg/WT embryos, Cre+: Tie2CreWT/TgRosa26-etv2-IRES-GFPTg/WT embryos.
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In this list of 50 genes, we found as well the endothelial-related gene Slit2 (14.66), and  the 
hematopoiesis-related genes BCL6b (12.93x), Notch4 (11.89x), and IL5Ra (9.51x). ESAM, 
that was identified as a target of Etsrp,128 was also upregulated in our system (7.66x). The same 
thing was true for Ldb2 (8.794x), Hapln1 (24.91x), BMP2 (5.11x),127 and Tie2 (5.69x).66
The 50 most downregulated genes are presented in Table 4. Etv2 has been described as an 
activator. Nevertheless we identified a quantity of downregulated genes. These hits could simply 
be indirect targets, Etv2 could  have a different mechanism of action than Etsrp, they could 
Fold 
change
Gene Symbol Chromosome
Genbank 
Accession
Gene Name
52.16 Dysf chr6 NM_001077694 dysferlin
33.83 C630004H02Rik chr11 NM_175454 RIKEN cDNA C630004H02 gene
28.25 S100a8 chr3 NM_013650 S100 calcium binding protein A8 (calgranulin A)
24.91 Hapln1 chr13 NM_013500 hyaluronan and proteoglycan link protein 1
23.49 Dhrs2 chr14 NM_027790 dehydrogenase/reductase member 2
17.15 S100a9 chr3 NM_009114 S100 calcium binding protein A9 (calgranulin B)
17.12 Rgs3 chr4 NM_019492 regulator of G-protein signaling 3
16.79 Tspan18 chr2 NM_183180 tetraspanin 18
16.34 Ifi203 chr1 NM_001045481 interferon activated gene 203
15.54 Pde2a chr7 NM_001143848 phosphodiesterase 2A, cGMP-stimulated
15.37 Fbp1 chr13 NM_019395 fructose bisphosphatase 1
15.31 Hopx chr5 NM_175606 HOP homeobox
15.22 S100a16 chr3 NM_026416 S100 calcium binding protein A16
15.07 Ifi203 chr1 NM_001045481 interferon activated gene 203
14.66 Slit2 chr5 NM_178804 slit homolog 2 (Drosophila)
14.02 Mrgpra2b chr7 NM_153101 MAS-related GPR, member A2B
14.01 Mrgpra6 chr7 NM_205821 MAS-related GPR, member A6
13.95 Etv2 chr7 NM_007959 ets variant gene 2
13.56 Mrgpra2a chr7 NM_001172588 MAS-related GPR, member A2A
13.35 Csgalnact1 chr8 NM_172753 chondroitin sulfate N-acetylgalactosaminyltransferase 1
12.93 Bcl6b chr11 NM_007528 B-cell CLL/lymphoma 6, member B
12.68 LOC677460 chr7 XM_001003789 similar to MAS-related GPR, member A4
12.54 chr1 lincRNA:chr1:175705225-175717250 reverse strand
11.89 Notch4 chr17 NM_010929 Notch gene homolog 4 (Drosophila)
11.57 Pnp2 chr14 NM_001123371 purine-nucleoside phosphorylase 2
11.56 chr6 XM_001472893 PREDICTED: Mus musculus hypothetical protein LOC100044678
11.40 Cdh5/VE-Cad chr8 NM_009868 cadherin 5
11.31 Tdrd5 chr1 NM_001134741 tudor domain containing 5
11.05 Mmrn1 chr6 NM_027613 multimerin 1
11.04 chr2 XM_001478824 Putative uncharacterized protein Fragment
10.36 chr1 lincRNA:chr1:175705225-175717250 reverse strand
10.31 Crisp3 chr17 NM_009639 cysteine-rich secretory protein 3
10.26 Kdr/Flk1 chr5 NM_010612 kinase insert domain protein receptor
10.22 Fgr chr4 NM_010208 Gardner-Rasheed feline sarcoma viral (Fgr) oncogene homolog
10.08 Clec1b chr6 NM_019985 C-type lectin domain family 1, member b
10.02 Pglyrp1 chr7 NM_009402 peptidoglycan recognition protein 1
9.99 Myct1 chr10 NM_026793 myc target 1
9.94 2310065F04Rik chr11 AK010044 RIKEN cDNA 2310065F04 gene
9.80 Cpa3 chr3 NM_007753 carboxypeptidase A3, mast cell
9.64 Serpina3g chr12 NM_009251 serine (or cysteine) peptidase inhibitor, clade A, member 3G
9.60 Clec4e chr6 NM_019948 C-type lectin domain family 4, member e
9.56 Galntl4 chr7 NM_173739 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase-like 4
9.51 Il5ra chr6 NM_008370 interleukin 5 receptor, alpha
9.35 Tdrd5 chr1 NM_001134741 tudor domain containing 5
9.35 Tac4 chr11 NM_053093 tachykinin 4
9.26 Ptprb chr10 NM_029928 protein tyrosine phosphatase, receptor type, B
9.21 Hopx chr5 NM_175606 HOP homeobox
8.88 Clec1b chr6 NM_019985 C-type lectin domain family 1, member b
8.81 Clec1b chr6 NM_019985 C-type lectin domain family 1, member b
Table 3. Microarray analysis data: 50 most upregulated genes in VE-Cad+CD45+ cells sorted from 
E10.5 Cre+ yolk sacs
Relative expression, compared to Cre- control. Bold: endothelial-, or hematopoietic-related genes. Cre-: 
Tie2CreWT/WTRosa26-etv2-IRES-GFPTg/WT embryos, Cre+: Tie2CreWT/TgRosa26-etv2-IRES-GFPTg/WT embryos.
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represent false hits, or Etv2 could have also a silencer activity.  Amongst these genes, we identified 
many hits related to macrophage function, such as complement components: Cfh (-39.82x), 
C1qb (-25.42x), C1qa(-20.44x), and C1qc (-20.12x), and Fcgrt (-19.49x). Which suggests that 
the cells coming from Cre+ yolk sac are indeed more immature in their hematopoietic phenotype 
than their Cre- counterparts. Mesenchymal collagen genes were also found to be enriched in the 
list of the downregulated genes: Col1a1 (-26.12x), and Col1a2 (-14.02x).
Fold 
change
Gene Symbol Chromosome
Genbank 
Accession
Gene Name
-39.82 Cfh chr1 NM_009888 complement component factor h
-37.43 Emr1 chr17 NM_010130 EGF-like module containing, mucin-like, hormone receptor-like sequence 1
-36.14 AI607873 chr1 XM_001479984 expressed sequence AI607873
-33.58 chr1 lincRNA:chr1:175653557-175671940 reverse strand
-32.68 Clec4a1 chr6 NM_199311 C-type lectin domain family 4, member a1
-32.26 chr1 lincRNA:chr1:175653557-175671940 reverse strand
-30.78 Emr1 chr17 NM_010130 EGF-like module containing, mucin-like, hormone receptor-like sequence 1
-29.45 Trem2 chr17 NM_031254 triggering receptor expressed on myeloid cells 2
-28.24 Timp2 chr11 NM_011594 tissue inhibitor of metalloproteinase 2
-26.99 Lpl chr8 NM_008509 lipoprotein lipase
-26.16 Col1a1 chr11 NM_007742 collagen, type I, alpha 1
-25.43 C1qb chr4 NM_009777 complement component 1, q subcomponent, beta polypeptide
-25.19 Ccl7 chr11 NM_013654 chemokine (C-C motif) ligand 7
-24.19 Itgb5 chr16 NM_010580 integrin beta 5
-24.11 Slc40a1 chr1 NM_016917 solute carrier family 40 (iron-regulated transporter), member 1
-23.76 5430435G22Rik chr1 NM_145509 RIKEN cDNA 5430435G22 gene
-23.61 Tgfbi chr13 NM_009369 transforming growth factor, beta induced
-23.46 Cd83 chr13 NM_009856 CD83 antigen
-23.30 chr1 lincRNA:chr1:175653557-175671940 reverse strand
-22.74 Lpl chr8 NM_008509 lipoprotein lipase
-22.19 chr1 lincRNA:chr1:175654606-175672031 reverse strand
-21.89 Atf3 chr1 NM_007498 activating transcription factor 3
-21.48 Slc15a3 chr19 NM_023044 solute carrier family 15, member 3
-20.60 Ahnak chr19 NM_009643 AHNAK nucleoprotein (desmoyokin)
-20.43 C1qa chr4 NM_007572 complement component 1, q subcomponent, alpha polypeptide
-20.13 C1qc chr4 NM_007574 complement component 1, q subcomponent, C chain
-19.94 Mrc1 chr2 NM_008625 mannose receptor, C type 1
-19.86 Gas6 chr8 NM_019521 growth arrest specific 6
-19.82 Ly86 chr13 NM_010745 lymphocyte antigen 86
-19.65 Nupr1 chr7 NM_019738 nuclear protein 1
-19.49 Fcgrt chr7 NM_010189 Fc receptor, IgG, alpha chain transporter
-19.42 P2ry6 chr7 NM_183168 pyrimidinergic receptor P2Y, G-protein coupled, 6
-18.41 Dab2 chr15 NM_023118 disabled homolog 2 (Drosophila)
-18.37 Pdlim4 chr11 NM_019417 PDZ and LIM domain 4
-18.01 Aif1 chr17 NM_019467 allograft inflammatory factor 1
-17.93 Ccl2 chr11 NM_011333 chemokine (C-C motif) ligand 2
-17.44 Gap43 chr16 NM_008083 growth associated protein 43
-17.32 Ctss chr3 NM_021281 cathepsin S
-16.96 Ccl12 chr11 NM_011331 chemokine (C-C motif) ligand 12
-16.77 Batf3 chr1 NM_030060 basic leucine zipper transcription factor, ATF-like 3
-15.88 Ckb chr12 NM_021273 creatine kinase, brain
-15.69 Pld4 chr12 NM_178911 phospholipase D family, member 4
-15.10 Lrp1 chr10 NM_008512 low density lipoprotein receptor-related protein 1
-14.97 Tmem51 chr4 NM_145402 transmembrane protein 51
-14.96 LOC100048875 chr9 XM_001472585 similar to chemokine receptor CX3CR1
-14.79 Mcoln2 chr3 NM_026656 mucolipin 2
-14.07 Ms4a6c chr19 NM_028595 membrane-spanning 4-domains, subfamily A, member 6C
-14.05 Slco2b1 chr7 NM_175316 solute carrier organic anion transporter family, member 2b1
-14.02 Col1a2 chr6 NM_007743 collagen, type I, alpha 2
-13.83 Fcrls chr3 NM_030707 Fc receptor-like S, scavenger receptor
-13.78 Cx3cr1 chr9 NM_009987 chemokine (C-X3-C) receptor 1
Table 4. Microarray analysis data: 50 most downregulated genes in VE-Cad+CD45+ cells sorted from 
E10.5 Cre+ yolk sacs
Relative expression, compared to Cre- control. Bold: mesenchymal-, or hematopoietic-related genes. Cre-: 
Tie2CreWT/WTRosa26-etv2-IRES-GFPTg/WT embryos, Cre+: Tie2CreWT/TgRosa26-etv2-IRES-GFPTg/WT embryos.
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Table 6. Microarray analysis data: expression levels of other endothelial/hematopoietic major 
transcription factors in VE-Cad+CD45+ cells sorted from E10.5 Cre+ yolk sacs
Other endothelial/hematopoietic major transcription factors that display a fold change in expression <5. 
Relative expression, compared to Cre- control. Cre-: Tie2CreWT/WTRosa26-etv2-IRES-GFPTg/WT embryos, 
Cre+: Tie2CreWT/TgRosa26-etv2-IRES-GFPTg/WT embryos.
Fold 
change
Gene Symbol Chromosome
Genbank 
Accession
Gene Name
4.03 Gata2 chr6 NM_008090 GATA binding protein 2
3.67 Erg chr16 NM_133659 avian erythroblastosis virus E-26 (v-ets) oncogene related
3.16 Gfi1b chr2 NM_008114 growth factor independent 1B
2.76 Eng/CD105 chr2 NM_001146350 endoglin
2.60 Meis1 chr11 NM_010789 Meis homeobox 1
2.16 Myb chr10 NM_010848 myeloblastosis oncogene
2.01 Lmo2 chr2 NM_008505 LIM domain only 2
1.66 Kit chr5 NM_001122733 kit oncogene
1.60 Fli1 chr9 NM_008026 Friend leukemia integration 1
1.54 Tal1/Scl chr4 NM_011527 T-cell acute lymphocytic leukemia 1
1.25 Runx1 chr16 NM_009821 runt related transcription factor 1
1.23 Lyl1 chr8 NM_008535 lymphoblastomic leukemia 1
1.12 Icam2 chr11 NM_010494 intercellular adhesion molecule 2
-1.11 Gata1 chrX NM_008089 GATA binding protein 1
-1.35 Bmp4 chr14 NM_007554 bone morphogenetic protein 4
Fold 
change
Gene Symbol Chromosome
Genbank 
Accession
Gene Name
8.30 Tjp1 chr7 NM_009386 tight junction protein 1
8.18 Nrarp chr2 NM_025980 Notch-regulated ankyrin repeat protein
7.66 Esam chr9 NM_027102 endothelial cell-specific adhesion molecule
7.65 Rasip1 chr7 NM_028544 Ras interacting protein 1
7.04 Klrb1c chr6 NM_001159904 killer cell lectin-like receptor subfamily B member 1C
6.51 Vegfc chr8 NM_009506 vascular endothelial growth factor C
6.48 Tgfbr3 chr5 NM_011578 transforming growth factor, beta receptor III
6.42 Bmp8a chr4 NM_007558 bone morphogenetic protein 8a
6.15 Zfpm2 chr15 NM_011766 zinc finger protein, multitype 2
6.12 Ecscr chr18 NM_001033141 endothelial cell-specific chemotaxis regulator
5.75 Cd93/AA4.1 chr2 NM_010740 CD93 antigen
5.73 Gimap4 chr6 NM_174990 GTPase, IMAP family member 4
5.69 Tek/Tie2 chr4 NM_013690 endothelial-specific receptor tyrosine kinase
5.19 Robo4 chr9 NM_028783 roundabout homolog 4 (Drosophila)
5.11 Bmp2 chr2 NM_007553 bone morphogenetic protein 2
-5.13 C5ar1 chr7 NM_001173550 complement component 5a receptor 1
-5.19 Cd86 chr16 NM_019388 CD86 antigen
-5.47 Bcl2a1d chr9 NM_007536 B-cell leukemia/lymphoma 2 related protein A1d
-5.74 Lifr chr15 NM_013584 leukemia inhibitory factor receptor
-6.14 Bmpr1a chr14 NM_009758 bone morphogenetic protein receptor, type 1A
-6.18 Cd14 chr18 NM_009841 CD14 antigen
-6.48 Tlr2 chr3 NM_011905 toll-like receptor 2
-7.05 Msr1 chr8 NM_031195 macrophage scavenger receptor 1
-7.24 Cd33 chr7 NM_001111058 CD33 antigen
-7.36 Cd68 chr11 NM_009853 CD68 antigen
-7.49 Bcl2a1c chr9 NM_007535 B-cell leukemia/lymphoma 2 related protein A1c
-7.52 Csf1r chr18 NM_001037859 colony stimulating factor 1 receptor
-7.68 Blnk chr19 NM_008528 B-cell linker
-7.71 Cfp chrX NM_008823 complement factor properdin
-7.90 Tlr13 chrX NM_205820 toll-like receptor 13
-8.01 Cfb chr17 NM_008198 complement factor B
-8.62 Hck chr2 NM_001172117 hemopoietic cell kinase
-9.20 chr12 AK088666 immunoglobulin heavy chain 6 (heavy chain of IgM) Gene
-10.32 Tlr1 chr5 NM_030682 toll-like receptor 1
-11.45 Etv5 chr16 NM_023794 ets variant gene 5
-12.45 C3ar1 chr6 NM_009779 complement component 3a receptor 1
-13.08 Col3a1 chr1 NM_009930 collagen, type III, alpha 1
-13.22 Fcgr1 chr3 NM_010186 Fc receptor, IgG, high affinity I
Table 5. Microarray analysis data: other endothelial-, hematopoietic-, or mesenchymal-related genes 
differentially expressed in VE-Cad+CD45+ cells sorted from E10.5 Cre+ yolk sacs
Remaining endothelial-, hematopoietic-, or mesenchymal-related genes that display a fold change in 
expression >5. Relative expression, compared to Cre- control. Cre-: Tie2CreWT/WTRosa26-etv2-IRES-GFPTg/
WT embryos, Cre+: Tie2CreWT/TgRosa26-etv2-IRES-GFPTg/WT embryos.
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Table 5 presents the rest of the genes that have been precedently associated to endothelial, 
hematopoietic, mesenchymal differentiation, and that are differentially expressed by at least 
a 5-fold change. Table 6 lists the major endothelial/hematopoietic transcription factors. We 
observed that Gata2, Erg, Gfi1b, Meis1, Myb, and Lmo2116 see their expression level increase at 
least 2x upon Etv2 overexpression. Which is consistent with what was shown in the two zebrafish 
experiments. Obviously, all the hits presented here will have to be verified by repeating this 
experiment a few more times, but this preliminary data seems fairly consistent with what can be 
found in the literature, and with what was shown by the other experiments.
We also prepared a B-cell assay, in which sorted VE-Cad+CD45+ cells were recultured for 14days, 
in serum-containing medium supplemented with SCF, Flt3L, and IL-7, on OP9 feeder layer. 
At the time of writing, the B-cell assay was still underway (day 12), and the data will thus be 
only presented in the oral defense of the project. From the look of the cultures, it would seem 
that both Cre+ and Cre- cells are proliferating, and that this proliferation is significantly more 
extensive in the Cre- control cells-containing wells.
5. Discussion
Effects of BMP and Wnt signaling inhibition on the differentiation of a Flk1+ extraembryonic mesoderm 
in vitro model
Using an in vitro differentiation system that mimics Flk1+ extraembryonic mesoderm, we were 
able to provide evidence that, after that stage, BMP and Wnt signaling still play a big role in 
the differentiation towards endothelial, and hematopoietic lineages. What is more, these effects 
appear to be cumulative, indicating these two pathways act cooperatively, as it was previously 
suggested.79  Moreover, our results seem to be consistent with similar experiments that have been 
done by an other group.81
BMP signaling suppression leaded to an expansion of the endothelial, and erythroid 
compartments, and in a restriction of the hematopoietic cell pool. An explanation for this 
could be that BMP signaling inhibition prevents commitment towards hematopoietic lineage. 
Thus, the endothelial cell compartment could be expanded through either the inability of 
Flk1+ extraembryonic mesoderm cells to become angioblasts, or the incapacity of hemogenic 
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endothelial cells to commit to a hematopoietic fate, or a combination of both. This promotion of 
the definitive endothelial fate by BMP signaling inhibition was further supported by the higher 
expression level of Sox17.123 We thus speculate that this effect might be mediated by inactivation 
of Runx1: interaction between BMP signaling and Runx1 has already been suggested in the 
literature.129 Moreover, in vivo, Runx1-expressing regions often overlap with BMP4 expression.78 
In addition, Runx1-/- mice have been shown to keep erythroid differentiation, but to lack other 
hematopoietic cell types, a phenotype close to what we observed in our culture system.70 In the 
future, a closer look at the erythroid cells that were obtained in the LDN-containing wells could 
be very informative on this matter, as these cells have been shown to be abnormal in the Runx1-
/- mice.62
Wnt signaling inhibition, on the other hand, appears to affect definitive hematopoiesis, but we 
did not observe an expansion of the erythroid and endothelial cell pools. This suggests that the 
mechanism of action is different. This idea is supported by the fact that Wnt and BMP signaling 
inhibition appear to act synergistically to suppress definitive hematopoiesis. Wnt signaling has 
been suggested to activate the Notch signaling pathway, which is a key factor in the transition 
towards definitive hematopoietic fate.67,130 There is thus a possibility that Wnt signaling 
suppression leads to reduced Notch activation, and thus to restricted transition from hemogenic 
endothelial cells to the definitive hematopoietic lineage. This hypothesis could be assessed by 
testing if inhibition of the Notch signaling pathway leads to a similar phenotype in the same 
culture system.
In the future, if our hypothesis turn out to be correct, they will have to be tested in vivo. We 
can thus imagine creating conditional knockout mice that lose ALK-2 and ALK-3, or TNKS-1 
and TNKS-2 expression at a precise time point, using either a Tet-off system and doxicycline 
injections, or a Cre-Lox system that excises these genes upon Flk1 expression, using a Flk1Cre 
construct.
Expansion of a VE-Cad+CD45+ population in the yolk sac upon Etv2 overexpression in mouse embryo
In this part of the project, we used a Cre conditional knock-in system that allowed the 
overexpression of Etv2 in the Tie2 compartment. It permitted us to gain more insight in the 
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mechanisms of action of what we think is the master gene of endothelial , and hematopoietic 
development in the mouse embryo. 
We were able to show that overexpressing Etv2 in the early endothelial compartment is 
embryonically lethal: the embryos die in utero around E11.5, presenting a bleeding phenotype, 
and some abnormal structures in the yolk sac vasculature. At day E9.5 and E10.5, the yolk sac of 
the Cre+ embryos presented a typical pattern consisting in clusters of transgene-expressing cells. 
With flow cytometry analysis, we noticed the expansion of a VE-Cad+CD45+ cell population 
in the yolk sac of E10.5 Cre+ embryos. The vast majority of these cells expressed the transgene, 
as well as c-Kit and CD41, contrarily to the same population isolated from Cre- embryos. We 
thus suggested that the transgene-expressing cells represent a more immature hematopoietic 
population than their control, transgene-negative counterparts.
We then tried to further characterized this Etv2-overexpressing cell population, and found out 
that they have extensive erythroid and myeloid potential. Also, they seemed to express higher 
levels of numerous endothelial-related genes, and lower expression of mesenchymal-, and 
macrophage-related genes, as assessed by microarray analysis. Many of the major endothelial/
hematopoietic transcription factors were upregulated as well, although to a lesser extent. 
One possible explanation for the phenotype observed in our system is illustrated by Figure 19. 
We think that hemogenic endothelial cells need to completely lose Etv2 expression in order to 
differentiate into definitive endothelial cells. Etv2 overexpression in those cells thus keeps them 
from doing so. This probably results in an accumulation of immature hemogenic endothelial 
cells. The data we obtained with the CFU-assay and from the look of the cells in the B-cell assay 
after 12 days of reculture indicate that hematopoietic differentiation is not much affected by the 
overexpression of Etv2. Thus, since there is an expanded pool of hemogenic endothelial cells, 
the pre-definitive-HSC number is also increased, which is reflected by the expansion of the VE-
Cad+CD45+ cell population in the E10.5 yolk sac. This hypothesis will need to be further tested: 
the cells obtained in the CFU-assay will have to be more carefully observed, to see if they are fully 
normal, especially in their marker gene expression signature (especially VE-Cad and c-Kit). The 
B-cell assay will give us more information on the defninitive hematopoietic stem cell potential of 
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the Etv2-overexpressing cells. The endothelial potential of these cells will also have to be tested, 
probably by culturing them in the presence of VEGF, and checking for the formation of vascular-
like structures.
The data that we accumulated with these experiments, combined with the finding that 
overexpression of Etv2 in the Sox17 and Vav compartment is not lethal, strongly suggests that 
Etv2 needs the cells in which it is expressed to be somehow primed to be responsive to it. It 
appears that the cells that already have downregulated Etv2 during their differentiation will not 
revert back to a state that is affected by its overexpression.  Also, we were able to obtain a good 
indication on the developmental window in which Etv2 downregulation is essential for the 
viability of the embryo: the cells that seem to be most affected by its overexpression are probably 
located in the yolk sac, and appear to be very similar to the ones we defined as hemogenic 
endothelial cells.
        Kôbe,  June 24th 2011
        Matteo Pluchinotta
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Figure 19. One possible explanation for the observed phenotype 
in the Tie2CreWT/TgRosa26-etv2-IRES-GFPTg/WT embryos
Etv2 overexpression keeps the hemogenic endothelial cells from 
differentiate further towards the endothelial lineage (red arrow). These 
cells stay thus in a more immature state. Hematopoietic differentiation, 
on the other hand, is not affected by Etv2 overexpression.
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8. Abbreviations used
Abbreviation  Meaning
2-ME   2-Mercaptoethanol
APC   Allophycocyanin
BFU-E   Burst-Forming Unit-Erythroid
BMP   Bone Morphogenic Protein
Bry   Brachyury
BSA   Bovine Serum Albumin 
CFU   Colony-Forming Unit
CFU-G   CFU-Granulocyte
CFU-GEMM  CFU-Granulocyte, Erythroid, Macrophage, Megakaryocyte 
CFU-GM  CFU-Granuolcyte, Macrophage 
CFU-M  CFU-Macrophage 
Co-Smad  Common-Smad
Cre   Cre-Recombinase
DNA   Deoxyribose Nucleic Acid
dpc   day post-coitum
Dvl   Dishvelled
E   Embryonic day
ES   Embryonic Stem
Etsrp   Ets-related protein
Etv2   Ets variant 2
FACS   Fluorescence-Activated Cell Sorting
FITC   Fluorescein Isothiocyanate
Flk1   Fetal liver kinase 1
Fz   Frizzled
G-CSF   Granulocyte-Colony-Stimulating Factor
HBSS   Hank’s balanced salt solution 
HDAC   Histone Deacetylase
HSC   Hematopoietic Stem Cell
ICAM2  Intercellular Adhesion Molecule 2
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iPS   induced Pluripotent Stem
KO-DMEM  Knock-out Dulbecco’s Modified Eagle’s Medium
mIL   mouse Interleukin
min   minute
MoAb   Monoclonal Antibody
NEAA   Non-Essential Amino Acids 
PBS   Phosphate-Buffered Saline
PCR   Polymerase Chain Reaction
PDGFRα  Platelet-Derived Growth Factor Receptor α
PE   Phycoerythrin
PECAM-1  Platelet Endothelial Cell Adhesion Molecule 1
PI   Prodidium Iodide
qRT-PCR  quantitative Reverse Transcriptase-PCR
R-Smad  Receptor-activated Smad 
rhEPO   recombinant human Erythropoietin
rmEPO   recombinant mouse Erythropoietin
RNA   Ribose Nucleic Acid
RT   Room Temperature
Runx1   Runt-related transcription factor 1
SCF   Stem Cell Factor
sec   second
SEM   Standard Error of the Mean
TGF-β   Transforming Growth Factor-β 
TNKS   Tankyrase
VE-Cad  Vascular Endothelial Cadherin
VEGF   Vascular Endothelial Growth Factor
VEGFR  Vascular Endothelial Growth Factor Receptor
αMEM   α-Minimal Essential Medium
